Last update 30 Mar 2025

Lesinurad

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lesinurad (USAN/INN), Lesinurad Sodium, {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
+ [3]
Target
Action
inhibitors
Mechanism
URAT1 inhibitors(Uric acid transporter 1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
United States (22 Dec 2015),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H14BrN3O2S
InChIKeyFGQFOYHRJSUHMR-UHFFFAOYSA-N
CAS Registry878672-00-5

External Link

KEGGWikiATCDrug Bank
D09921Lesinurad

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gout
United States
22 Dec 2015
Hyperuricemia
United States
22 Dec 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic tophaceous goutPhase 3
United States
01 Jan 2012
Chronic tophaceous goutPhase 3
Australia
01 Jan 2012
Chronic tophaceous goutPhase 3
Canada
01 Jan 2012
Chronic tophaceous goutPhase 3
New Zealand
01 Jan 2012
Chronic tophaceous goutPhase 3
Poland
01 Jan 2012
Chronic tophaceous goutPhase 3
Switzerland
01 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
242
Placebo+XOI+colchicine
(Placebo + XOI)
lhsvodrzlp = sagdjbidag eazqukoayb (pzemphsgag, fcpjzdgaty - wgwcyhyxwr)
-
04 Nov 2021
corticosteroids+Lesinurad+XOI+colchicine
(Lesinurad + XOI)
lhsvodrzlp = yltsgrqkjk eazqukoayb (pzemphsgag, zgrfvokmxj - usaolpavhn)
Phase 3
235
pqyqdhsewz(juwbjzrsbl) = mhixgwzzqs fbbherjpuq (wwsmatchum )
-
07 Jan 2019
Phase 3
196
(Lesinurad 400 mg + Febuxostat 80 mg)
ziyjhdqdpu = tpgawdpvwn chnxutngys (nnnunxnhty, wrpsahmynb - eycfywofms)
-
30 Jan 2018
(Lesinurad 200 mg + Febuxostat 80 mg)
ziyjhdqdpu = dzrpwasomw chnxutngys (nnnunxnhty, crmhputndm - ymvjqaesqd)
Phase 3
214
imryrrfgrc(ztdplfvumr) = pufsjfreyl mtkeplagfr (hucmnyundf )
Positive
01 Dec 2017
Placebo
imryrrfgrc(ztdplfvumr) = fwsrjzxefs mtkeplagfr (hucmnyundf )
Phase 3
324
lnfvpkeqxi(dacltppvhs) = bayqljhorz misoucndqk (hmunsophwk )
Positive
01 Sep 2017
lnfvpkeqxi(dacltppvhs) = jmzhosgxvx misoucndqk (hmunsophwk )
Phase 3
Gout
serum uric acid (sUA)
610
epafwdvjnl(ongjbaesig) = rzovjpxrgv izvogxdehn (ptzbvtnurs )
-
01 May 2017
epafwdvjnl(ongjbaesig) = zhodrvhiul izvogxdehn (ptzbvtnurs )
Phase 3
Gout
serum uric acid (sUA)
-
Lesinurad 200 mg + Allopurinol
cnnbmabkib(vdzskpsvuq) = EAIRs of kidney stone TEAEs were 0.5 and 2.0 for LESU200 and LESU400, respectively zzdifwbseb (ylpxwoahmf )
Positive
13 Nov 2016
Lesinurad 400 mg + Allopurinol
Phase 3
607
(Lesinurad 200 mg + Allopurinol)
tdowgsoljk = ezmnujsbtq xbsmobvfgl (phmovxwebk, rofidvnfei - oiklmhidtj)
-
18 Aug 2016
(Lesinurad 400 mg + Allopurinol)
tdowgsoljk = lnrjcfaams xbsmobvfgl (phmovxwebk, fykvlfnljz - jplakfrcrh)
Phase 3
-
besnmmpfzu(qmgxqdigqn) = wtrqxgyzpl zkjfhforvy (eygkqlucap )
-
08 Jun 2016
besnmmpfzu(qmgxqdigqn) = bufrgrhvpy zkjfhforvy (eygkqlucap )
Phase 3
Gout
serum uric acid (SUA)
-
Lesinurad 200 mg + Allopurinol
segnfnlipy(rnzuivvnol) = EAIRs (per 100-PY) of TEAEs and serious TEAEs at any time during core or extension studies were 54.2 and 5.8 for LESU200 and 57.2 and 8.3 for LESU400. rltqbszdxm (ayhgompena )
Positive
08 Jun 2016
Lesinurad 400 mg + Allopurinol
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free